PUBLICATION
Anticonvulsant activity of melatonin and its success in ameliorating epileptic comorbidity-like symptoms in zebrafish
- Authors
- Ren, Q., Gao, D., Mou, L., Zhang, S., Zhang, M., Li, N., Sik, A., Jin, M., Liu, K.
- ID
- ZDB-PUB-211027-9
- Date
- 2021
- Source
- European Journal of Pharmacology 912: 174589 (Journal)
- Registered Authors
- Keywords
- Anxiety, Depression, Glutathione metabolism, Network pharmacology
- MeSH Terms
-
- Animals
- Anticonvulsants/pharmacology*
- Anticonvulsants/therapeutic use
- Behavior, Animal/drug effects
- Cluster Analysis
- Disease Models, Animal
- Epilepsy/chemically induced
- Epilepsy/drug therapy*
- Epilepsy/genetics
- Gene Expression Regulation/drug effects
- Glutathione/genetics
- Glutathione/metabolism
- Locomotion/drug effects
- Melatonin/pharmacology*
- Melatonin/therapeutic use
- Network Pharmacology
- Pentylenetetrazole/toxicity
- Protein Interaction Maps/drug effects
- Receptor, Melatonin, MT1/antagonists & inhibitors
- Receptor, Melatonin, MT1/metabolism
- Receptor, Melatonin, MT2/antagonists & inhibitors
- Receptor, Melatonin, MT2/metabolism
- Seizures/chemically induced
- Seizures/drug therapy
- Seizures/genetics
- Zebrafish
- PubMed
- 34699755 Full text @ Eur. J. Pharmacol.
Citation
Ren, Q., Gao, D., Mou, L., Zhang, S., Zhang, M., Li, N., Sik, A., Jin, M., Liu, K. (2021) Anticonvulsant activity of melatonin and its success in ameliorating epileptic comorbidity-like symptoms in zebrafish. European Journal of Pharmacology. 912:174589.
Abstract
Epilepsy is one of common neurological disorders, greatly distresses the well-being of the sufferers. Melatonin has been used in clinical anti-epileptic studies, but its effect on epileptic comorbidities is unknown, and the underlying mechanism needs further investigation. Herein, by generating PTZ-induced zebrafish seizure model, we carried out interdisciplinary research using neurobehavioral assays, bioelectrical detection, molecular biology, and network pharmacology to investigate the activity of melatonin as well as its pharmacological mechanisms. We found melatonin suppressed seizure-like behavior by using zebrafish regular locomotor assays. Zebrafish freezing and bursting activity assays revealed the ameliorative effect of melatonin on comorbidity-like symptoms. The preliminary screening results of neurobehavioral assays were further verified by the expression of key genes involved in neuronal activity, neurodevelopment, depression and anxiety, as well as electrical signal recording from the midbrain of zebrafish. Subsequently, network pharmacology was introduced to identify potential targets of melatonin and its pathways. Real-time qPCR and protein-protein interaction (PPI) were conducted to confirm the underlying mechanisms associated with glutathione metabolism. We also found that melatonin receptors were involved in this process, which were regulated in response to melatonin exposure before PTZ treatment. The antagonists of melatonin receptors affected anticonvulsant activity of melatonin. Overall, current study revealed the considerable ameliorative effects of melatonin on seizure and epileptic comorbidity-like symptoms and unveiled the underlying mechanism. This study provides an animal model for the clinical application of melatonin in the treatment of epilepsy and its comorbidities.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping